Skip to content

Clinical Study on microorganism brain-gut-axis and Immune Mechanism in Patients with Insomnia belonging to the Spleen Deficiency from the Changes of Intestinal Microflora

Clinical Study on microorganism brain-gut-axis and Immune Mechanism in Patients with Insomnia belonging to the Spleen Deficiency from the Changes of Intestinal Microflora

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011110
Enrollment
Unknown
Registered
2017-04-10
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non organic insomnia

Interventions

Spleen Deficiency Group:Granule of Buzhong Yiqi Tang
Spleen Deficiency with Stomach Heat Syndrome Group:Granule of Bupiwei Xieyinhuo Shengyang Tang
Qi Deficiency Healthy People Group:no treatment

Sponsors

Guangdong Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: The Group of insomnia: 1. Conform to the western medicine diagnostic criteria of insomnia; 2. Sleep latency is over 30 minutes, and/or wake up at night more than 2 times per night, and/or the total sleep time<6 hours. Duration of those symptoms are more than 1 months; 3. Conform to the diagnostic criteria of insomnia in TCM; 4. Aged 18 to 55 years old; 5. Stable vital signs, conscious, have certain expression and cognitive ability; 6. Voluntary trial and signed informed consent. The non-insomnia group: 1. Conformed to the standard of spleen and stomach qi deficiency corporeity; 2. No significant organic diseases or psychosis and sleep disorders; 3. Aged 18-55 years old; 4. Have certain expression and cognitive ability; 5. Voluntary trial and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Does not conform to the inclusion criteria; 2. Pregnant or lactating patients; 3. Infection and fever in the last week; 4. Participated in other clinical trials in the past three months; 5. Previous history of gastrointestinal disease or gastrointestinal surgery.Patients with severe primary diseases such as cardiovascular, pulmonary, liver, kidney and hematopoietic systems; 6. Insomnia comorbid depression, anxiety, schizophrenia, mania, the standard score of SAS is=60, the standard score of SDS is=62; 7. Patients with a history of epilepsy, OSAHS, COPD, bipolar disorder, mental retardation, cognitive impairment, restless legs syndrome, etc.; 8. Within 6 months, use antibiotics, corticosteroids,immunomodulator , flora regulator and other drugs; 9. In the past 2 weeks, use sedative hypnotics, antipsychotic drugs,gastrointestinal motility drugs, laxative, antidiarrheal agent and other drugs; 10. BMI =28kg/m2 or BMI18.

Design outcomes

Primary

MeasureTime frame
PSQI reduction rate;

Secondary

MeasureTime frame
SAS;SDS;the level of blood cortisol;Composition and proportion of intestinal flora;IL-1ß;IL-6;TNF-a;IFN;IL-10;TNF-ß;

Countries

China

Contacts

Public ContactLi Yan

Guangdong Provincial Hospital of TCM

janeliyan2002@163.com+86 13556054660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026